Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.84
+0.40003.22%
Post-market: 13.020.1800+1.40%19:50 EDT
Volume:3.35M
Turnover:43.22M
Market Cap:1.80B
PE:-3.84
High:13.13
Open:12.65
Low:12.65
Close:12.44
52wk High:28.25
52wk Low:7.95
Shares:140.00M
Float Shares:137.56M
Volume Ratio:0.92
T/O Rate:2.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3456
EPS(LYR):-3.8100
ROE:-55.44%
ROA:-30.14%
PB:2.47
PE(LYR):-3.37

Loading ...

Intellia grants 67,150 inducement RSUs to 13 new employees under 2024 plan

Reuters
·
Apr 04

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 04

Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?

Simply Wall St.
·
Mar 10

Intellia Therapeutics Awards 16,500 RSU Inducement Grants Under 2024 Plan

Reuters
·
Mar 07

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Mar 07

Intellia Therapeutics Raised to Buy From Hold by Jones Trading

Dow Jones
·
Mar 04

Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 04

Stock Track | Intellia Therapeutics Soars 5.77% in Pre-Market After Analyst Upgrade to Buy

Stock Track
·
Mar 04

Intellia Therapeutics Inc : Jonestrading Raises to Buy From Hold

THOMSON REUTERS
·
Mar 04

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

Stock Track | Intellia Therapeutics Plummets 7.34% Intraday on Dilution Fears from $400 Million Stock Sale Plan

Stock Track
·
Mar 03

Intellia Presents Three-Year Lonvo-z Data Showing 96% HAE Attack Reduction

Reuters
·
Mar 03

RBC Capital Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)

TIPRANKS
·
Mar 03

Intellia Therapeutics price target lowered to $48 from $54 at Canaccord

TIPRANKS
·
Mar 03

Intellia Therapeutics, Inc. : Wells Fargo Raises Target Price to $15 From $12

THOMSON REUTERS
·
Mar 03

Stock Track | Intellia Therapeutics Plunges 6.02% in Pre-market on $400 Million Stock Sale Plan

Stock Track
·
Mar 03

Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement

Stock Track
·
Mar 03

Intellia Therapeutics Inc - Entered Sale Agreement With Jefferies for up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Mar 03

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 03

Intellia Therapeutics price target raised to $27 from $26 at Chardan

TIPRANKS
·
Mar 03